A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)
Ravi Vij, Jennifer Le-Rademacher, Kristina Laumann, Vera Hars, Kouros Owzar, Tsiporah Shore, Sumithira Vasu, Amanda Cashen, Luis Isola, Thomas Shea, Margarida DeMagalhaes-Silverman, David Hurd, Kenneth Meehan, Frank Beardell, Steven Devine
Dive into the research topics of 'A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)'. Together they form a unique fingerprint.